Bigelow Investment Advisors LLC Acquires 27 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Bigelow Investment Advisors LLC boosted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.9% during the first quarter, Holdings Channel.com reports. The firm owned 1,420 shares of the company’s stock after acquiring an additional 27 shares during the period. Bigelow Investment Advisors LLC’s holdings in IDEXX Laboratories were worth $596,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the business. Hurley Capital LLC purchased a new stake in shares of IDEXX Laboratories during the 4th quarter valued at about $29,000. Rialto Wealth Management LLC bought a new stake in IDEXX Laboratories during the fourth quarter worth approximately $30,000. Colonial Trust Co SC raised its position in IDEXX Laboratories by 84.8% during the fourth quarter. Colonial Trust Co SC now owns 85 shares of the company’s stock valued at $35,000 after purchasing an additional 39 shares during the period. Kestra Investment Management LLC bought a new stake in shares of IDEXX Laboratories in the 4th quarter valued at approximately $38,000. Finally, Itau Unibanco Holding S.A. lifted its stake in shares of IDEXX Laboratories by 540.0% in the 4th quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company’s stock valued at $40,000 after purchasing an additional 81 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

Insider Activity

In related news, Director M Anne Szostak sold 1,260 shares of the stock in a transaction that occurred on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total value of $645,548.40. Following the transaction, the director now owns 1,801 shares of the company’s stock, valued at $922,724.34. This represents a 41.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.98% of the company’s stock.

Analyst Ratings Changes

IDXX has been the topic of several analyst reports. Stifel Nicolaus increased their price target on IDEXX Laboratories from $460.00 to $510.00 and gave the company a “hold” rating in a report on Monday, May 19th. Leerink Partners increased their target price on shares of IDEXX Laboratories from $515.00 to $580.00 and gave the company an “outperform” rating in a research note on Wednesday, June 11th. Morgan Stanley raised their target price on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an “overweight” rating in a report on Monday, May 5th. Finally, Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Friday, May 30th. Four analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus target price of $546.00.

IDEXX Laboratories Stock Down 0.1%

NASDAQ:IDXX opened at $519.85 on Thursday. The company has a market cap of $41.81 billion, a price-to-earnings ratio of 48.05, a price-to-earnings-growth ratio of 3.80 and a beta of 1.55. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $530.73. The company has a current ratio of 1.16, a quick ratio of 0.81 and a debt-to-equity ratio of 0.31. The stock has a fifty day simple moving average of $481.39 and a 200-day simple moving average of $446.39.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, topping the consensus estimate of $2.93 by $0.03. The company had revenue of $998.43 million for the quarter, compared to the consensus estimate of $998.25 million. IDEXX Laboratories had a net margin of 22.76% and a return on equity of 57.35%. The firm’s revenue was up 3.6% compared to the same quarter last year. During the same quarter last year, the firm posted $2.71 EPS. Analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.